Agenus (NASDAQ:AGEN) Upgraded to Buy at Wall Street Zen

Agenus (NASDAQ:AGEN) was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued on Saturday.

Several other research firms also recently commented on AGEN. Robert W. Baird upped their price objective on Agenus from $4.00 to $6.00 and gave the company a “neutral” rating in a research note on Wednesday, June 4th. B. Riley reissued a “buy” rating on shares of Agenus in a report on Monday, April 21st. Finally, HC Wainwright raised shares of Agenus from a “neutral” rating to a “buy” rating and set a $25.00 target price on the stock in a report on Wednesday, June 4th.

Agenus Trading Up 0.8%

Agenus stock opened at $4.80 on Friday. Agenus has a 12 month low of $1.38 and a 12 month high of $7.34. The business’s 50 day simple moving average is $5.42 and its 200 day simple moving average is $3.67. The company has a market cap of $131.62 million, a price-to-earnings ratio of -0.55 and a beta of 1.62.

Agenus (NASDAQ:AGEN) last posted its quarterly earnings data on Monday, May 12th. The biotechnology company reported ($1.03) EPS for the quarter, beating the consensus estimate of ($1.61) by $0.58. The firm had revenue of $24.07 million during the quarter, compared to analysts’ expectations of $26.38 million. As a group, equities research analysts forecast that Agenus will post -12.55 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. B. Riley Financial Inc. purchased a new position in Agenus in the fourth quarter worth $2,074,000. Siren L.L.C. purchased a new stake in Agenus during the first quarter valued at about $752,000. AQR Capital Management LLC boosted its position in Agenus by 3,080.3% during the first quarter. AQR Capital Management LLC now owns 441,486 shares of the biotechnology company’s stock valued at $664,000 after buying an additional 427,604 shares during the period. Gilead Sciences Inc. purchased a new stake in Agenus during the fourth quarter valued at about $635,000. Finally, Strs Ohio purchased a new stake in Agenus during the first quarter valued at about $214,000. Institutional investors own 61.46% of the company’s stock.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.